Comparing Trials Studying Treatment Intensification In mHSPC

Comparative Analysis With Other mHSPC Trials

Key Themes:

• Comparison between ARANOTE and other intensification trials (ARCHES, TITAN, LATITUDE)
• Differences in patient populations and trial design
• Unique attributes of various androgen receptor pathway inhibitors

Expert Insights:

• Dr Shore compared darolutamide's performance in ARANOTE to other agents: enzalutamide (ARCHES), apalutamide (TITAN), and abiraterone (LATITUDE).

While all agents demonstrated benefit when combined with androgen deprivation therapy, Dr Shore noted important differences in adverse effect profiles, tolerability, and patterns of adoption in clinical practice.